Surrozen Q1 Revenue Hits $5M, Exceeds Consensus
Reports Q1 revenue $5M, consensus $4M. The company said, "Surrozen remains focused on advancing a new generation of ophthalmology therapeutics that are built on a foundation of Wnt pathway biology. Surrozen's pipeline leverages its Wnt biology expertise and antibody technologies to develop therapeutics targeting ophthalmic diseases with significant unmet medical needs."
Trade with 70% Backtested Accuracy
Analyst Views on SRZN
About SRZN
About the author
Surrozen Reports Strong Q1 Revenue Growth Despite Losses
- Significant Revenue Growth: Surrozen reported Q1 revenue of $5 million, reflecting a remarkable year-over-year increase of 410.2%, indicating a strong market demand for its offerings, despite ongoing losses, which suggests improving market acceptance of its products or services.
- Earnings Performance: The company posted a non-GAAP EPS of -$11.65, which, while indicating substantial losses, contrasts sharply with the revenue growth, highlighting the need for the company to focus on cost control and profitability as it expands its operations.
- Cash Position: Surrozen ended the quarter with cash and cash equivalents of $106.9 million, ensuring sufficient operational funding for the upcoming quarters, which supports its research and development as well as market expansion plans.
- Market Outlook: Despite the losses, Surrozen's strong revenue growth and ample cash reserves provide a solid foundation for future product development and marketing efforts, potentially attracting investor interest in its long-term growth prospects.
Surrozen Reports Increased Losses in FY Results
- Poor Financial Performance: Surrozen's FY report reveals a GAAP EPS of -$32.37 and revenue of $3.47 million, a 67.4% year-over-year decline, missing market expectations and highlighting significant challenges in revenue generation.
- Improved Cash Position: As of December 31, 2025, Surrozen reported cash and cash equivalents of $89.2 million, up from $81.3 million on September 30, 2025, and $34.6 million on December 31, 2024, indicating some improvement in cash management.
- Funding Activities Progress: In January 2026, Surrozen secured $26.9 million in net proceeds from its at-the-market sales program and raised an additional $3.3 million from warrant exercises in February and March, providing extra operational funding.
- Market Reaction Outlook: Despite improvements in cash flow, ongoing losses and declining revenues may negatively impact investor confidence, necessitating close monitoring of future market performance.
Surrozen Reports FY EPS of USD -32.37
Market Overview: The S&P 500 index has shown a slight decline, reflecting investor caution amid ongoing economic uncertainties.
Sector Performance: Technology and consumer discretionary sectors have experienced notable fluctuations, impacting overall market sentiment.
Economic Indicators: Recent economic data suggests mixed signals, with inflation concerns continuing to influence market dynamics.
Investor Sentiment: Analysts indicate that investor sentiment remains cautious, with many awaiting clearer signals from upcoming economic reports.
Surrozen Grants Stock Options to Attract New Employee
- Stock Option Grant: On February 17, 2026, Surrozen granted a total of 3,070 stock options to a newly hired non-executive employee, aimed at attracting talent and enhancing the company's competitive edge, with an exercise price of $24.53 per share reflecting confidence in future growth.
- Incentive Plan Context: The stock option grant is part of Surrozen's 2025 Equity Inducement Plan, compliant with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's strategic focus on attracting and retaining key talent.
- Vesting Schedule: The stock options will vest over four years, with 25% vesting on the first anniversary of the hire date and the remaining shares vesting monthly thereafter, ensuring employee commitment and stability for the company.
- Biotech Outlook: Surrozen is focused on developing Wnt signaling-based therapeutics to address unmet medical needs in ocular diseases, and the stock option grant helps attract professionals with relevant expertise, driving innovation and growth in the biotechnology sector.
Surrozen Reports Q2 Profit on Gains
Financial Performance: Surrozen reported a GAAP EPS of $2.55 for Q2 2025, significantly exceeding expectations due to non-cash gains, while also achieving a net income of $39.7 million despite ongoing operating losses and increased research expenses.
Pipeline and Strategy: The company is advancing its ophthalmology drug candidates SZN-8141 and SZN-8143 targeting retinal diseases, with plans to submit an IND application in 2026, while relying on strategic partnerships for revenue and expertise amidst challenges in clinical trial timelines and cash management.
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
Leadership Changes and Advisory Board Formation: Surrozen has appointed Daniel Chao, M.D., Ph.D., as Vice President of Clinical Development and established a Clinical Advisory Board of leading retinal specialists to enhance its ophthalmology pipeline focused on severe eye diseases.
Financial Performance and Pipeline Progress: The company reported a net income of $39.7 million for Q2 2025, attributed to increased research service revenue and a strong cash position, while advancing its lead candidates SZN-8141 and SZN-8143 towards clinical trials.
Surrozen Reports Strong Q1 Revenue Growth Despite Losses
- Significant Revenue Growth: Surrozen reported Q1 revenue of $5 million, reflecting a remarkable year-over-year increase of 410.2%, indicating a strong market demand for its offerings, despite ongoing losses, which suggests improving market acceptance of its products or services.
- Earnings Performance: The company posted a non-GAAP EPS of -$11.65, which, while indicating substantial losses, contrasts sharply with the revenue growth, highlighting the need for the company to focus on cost control and profitability as it expands its operations.
- Cash Position: Surrozen ended the quarter with cash and cash equivalents of $106.9 million, ensuring sufficient operational funding for the upcoming quarters, which supports its research and development as well as market expansion plans.
- Market Outlook: Despite the losses, Surrozen's strong revenue growth and ample cash reserves provide a solid foundation for future product development and marketing efforts, potentially attracting investor interest in its long-term growth prospects.
Surrozen Reports Increased Losses in FY Results
- Poor Financial Performance: Surrozen's FY report reveals a GAAP EPS of -$32.37 and revenue of $3.47 million, a 67.4% year-over-year decline, missing market expectations and highlighting significant challenges in revenue generation.
- Improved Cash Position: As of December 31, 2025, Surrozen reported cash and cash equivalents of $89.2 million, up from $81.3 million on September 30, 2025, and $34.6 million on December 31, 2024, indicating some improvement in cash management.
- Funding Activities Progress: In January 2026, Surrozen secured $26.9 million in net proceeds from its at-the-market sales program and raised an additional $3.3 million from warrant exercises in February and March, providing extra operational funding.
- Market Reaction Outlook: Despite improvements in cash flow, ongoing losses and declining revenues may negatively impact investor confidence, necessitating close monitoring of future market performance.
Surrozen Reports FY EPS of USD -32.37
Market Overview: The S&P 500 index has shown a slight decline, reflecting investor caution amid ongoing economic uncertainties.
Sector Performance: Technology and consumer discretionary sectors have experienced notable fluctuations, impacting overall market sentiment.
Economic Indicators: Recent economic data suggests mixed signals, with inflation concerns continuing to influence market dynamics.
Investor Sentiment: Analysts indicate that investor sentiment remains cautious, with many awaiting clearer signals from upcoming economic reports.
Surrozen Grants Stock Options to Attract New Employee
- Stock Option Grant: On February 17, 2026, Surrozen granted a total of 3,070 stock options to a newly hired non-executive employee, aimed at attracting talent and enhancing the company's competitive edge, with an exercise price of $24.53 per share reflecting confidence in future growth.
- Incentive Plan Context: The stock option grant is part of Surrozen's 2025 Equity Inducement Plan, compliant with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's strategic focus on attracting and retaining key talent.
- Vesting Schedule: The stock options will vest over four years, with 25% vesting on the first anniversary of the hire date and the remaining shares vesting monthly thereafter, ensuring employee commitment and stability for the company.
- Biotech Outlook: Surrozen is focused on developing Wnt signaling-based therapeutics to address unmet medical needs in ocular diseases, and the stock option grant helps attract professionals with relevant expertise, driving innovation and growth in the biotechnology sector.
Surrozen Reports Q2 Profit on Gains
Financial Performance: Surrozen reported a GAAP EPS of $2.55 for Q2 2025, significantly exceeding expectations due to non-cash gains, while also achieving a net income of $39.7 million despite ongoing operating losses and increased research expenses.
Pipeline and Strategy: The company is advancing its ophthalmology drug candidates SZN-8141 and SZN-8143 targeting retinal diseases, with plans to submit an IND application in 2026, while relying on strategic partnerships for revenue and expertise amidst challenges in clinical trial timelines and cash management.
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
Leadership Changes and Advisory Board Formation: Surrozen has appointed Daniel Chao, M.D., Ph.D., as Vice President of Clinical Development and established a Clinical Advisory Board of leading retinal specialists to enhance its ophthalmology pipeline focused on severe eye diseases.
Financial Performance and Pipeline Progress: The company reported a net income of $39.7 million for Q2 2025, attributed to increased research service revenue and a strong cash position, while advancing its lead candidates SZN-8141 and SZN-8143 towards clinical trials.
